



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/900,278	07/06/2001	Magdy A. Eletreby	265/248	8634
41696	7590	06/28/2006		
VISTA IP LAW GROUP LLP 12930 Saratoga Avenue Suite D-2 Saratoga, CA 95070			EXAMINER GILLIGAN, CHRISTOPHER L	
			ART UNIT 3626	PAPER NUMBER

DATE MAILED: 06/28/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b> 09/900,278	<b>Applicant(s)</b> ELETREBY ET AL.	
	<b>Examiner</b> Luke Gilligan	<b>Art Unit</b> 3626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 07 April 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 49-61 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 49-61 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/14/06 has been entered.

***Response to Amendment***

2. In the amendment filed 4/14/06, the following has occurred: claim 49 has been amended and claims 54-61 have been added. Now claims 49-61 are presented for examination.

***Claim Objections***

3. Claim 54 is objected to because of the following informalities: Claim 54 recites the phrase "updating a patient database with a drug therapy regimen for the patient, the drug therapy regimen." It appears the phrase "the drug therapy regimen" was inadvertently added to the end of this step. For examination purposes, the Examiner will disregard this portion of the limitation. Appropriate correction is required.

***Claim Rejections - 35 USC § 103***

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 3626

5. Claims 49-57 and 59-61 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schrier et al., U.S. Patent No. 6,317,719 in view of Bloom et al., U.S. Patent No. 6,070,761 and further in view of Akers et al., U.S. Patent No. 6,112,182.

6. As per claim 49, Schrier teaches a method of managing the pharmaceutical care of a patient using one or more software-accessible databases comprising the steps of: updating a patient database with a drug therapy regimen for the patient, the drug therapy regimen comprising an identification of each drug prescribed to the patient, a frequency per day for each drug, and a daily dosage for each drug (see column 14, lines 15-20); updating the patient database with patient data, the patient data comprising any disease states and allergies for the patient (see column 6, lines 4-11); querying a clinical database with the drug therapy regimen and patient data, wherein the querying step further comprises identifying: (a) allergies the patient has for any of the prescribed drugs (see column 3, lines 39-46); (b) drug-drug interactions for any of the prescribed drugs (see column 3, lines 39-46); (c) dosage irregularities (see column 3, lines 39-46); (d) drug-disease contraindications (see column 3, lines 39-46); (g) adverse drug reactions (see column 3, lines 39-46); and (h) untreated disease states (see column 8, lines 36-40); and generating a report based on the querying step (see column 3, lines 41-48).

7. Schrier does not explicitly teach identifying therapeutic duplications or drugs in the drug therapy regimen without a medical indication. Bloom teaches an automated medication management system that includes the functions of identifying therapeutic duplications and drugs in the drug therapy regimen without a medical indication (see column 11, lines 10-33). It would have been obvious to one of ordinary skill in the art at the time of the invention to add such functionality to the existing drug-patient analysis element of Schrier. One of ordinary skill in the art would have been motivated to add such functionality for the purpose of enhancing relevant

Art Unit: 3626

knowledge provided to physicians for making treatment determinations (see column 1, lines 51-54 of Schrier).

8. Schrier also does not explicitly teach that each drug in the clinical database is associated with a multi-character therapeutic cross reference code, wherein a first set of characters represent a class of drugs, a second set of characters represents a subclass of drugs, and a third set of characters represent a specific drug, and wherein the identification is based in part on a comparison of the multi-character therapeutic cross reference code with the patient database records. However, Akers teaches an integrated healthcare management system which maintains a clinical database of drugs that each are associated with a multi-character therapeutic cross reference code, wherein a first set of characters represent a class of drugs, a second set of characters represents a subclass of drugs, and a third set of characters represent a specific drug (see column 5, lines 18-21 and Figure 4, the Examiner is interpreting the "generic class" to be a form of "class of drugs," the "therapeutic class" to be a form of "subclass of drugs," and the "drug name or NDC" to be form of "specific drug"). Akers further teaches identifying certain "triggers" by a comparison of the multi-character therapeutic cross reference code with the patient database records (see column 5, lines 1-6 and Figure 4). It would have been obvious to one of ordinary skill in the art at the time of the invention to incorporate such coding features with the combined teachings of Schrier and Bloom. One of ordinary skill in the art would have been motivated to combine such a feature as this for the purpose of better providing appropriate information and delivery of healthcare services (see column 2, lines 12-24 of Akers).

9. As per claim 50, Schrier in view of Bloom and Akers teach the method of claim 49 as described above. Schrier further teaches the querying step identifies the following additional information for each patient: (i) information regarding use or efficacy of any of the prescribed

Art Unit: 3626

drugs (see column 3, lines 46-48); and (j) information regarding patient compliance (see column 6, lines 4-10).

10. As per claim 51, Schrier in view of Bloom and Akers teach the method of claim 50 as described above. Schrier further teaches the querying step identifies the following additional information for each patient: (k) information regarding an assessment of the educational needs of the patient (see column 6, lines 33-35, the Examiner considers patient age to be indicative of educational needs); (l) information regarding the financial circumstances of the patient (see column 10, lines 45-48).

11. As per claim 52, Schrier in view of Bloom and Akers teach the method of claim 49 as described above. Schrier further teaches the drug therapy regimen for the patient comprises a plurality of drugs prescribed by more than one physician (see column 7, line 56 – column 8, line 3).

12. As per claim 53, Schrier in view of Bloom and Akers teach the method of claim 49 as described above. Schrier further teaches modifying the drug therapy regimen based on the report (see column 7, line 64 – column 8, line 3).

13. Claims 54 and 57 recite substantially similar limitations to those already addressed in claim 49 and, as such, are rejected for similar reasons as given above.

14. As per claim 55, Schrier in view of Bloom and Akers teach the method of claim 54 as described above. Although the combination of Schrier in view of Bloom and Akers does not explicitly teach that the multi-character therapeutic cross reference code comprises an eight character code with the class, subclass, and specific drug represented as two, four, and two characters respectively, these differences are only found in the non-functional data that labels the class, subclass, and specific drug indicated by the multi-character therapeutic cross reference code. Thus, this descriptive material will not distinguish the claimed invention from

Art Unit: 3626

the prior art in terms of patentability, *see Cf. In re Gulack*, 703 F.2d 1381, 1385, 217 USPQ 401, 404 (Fed. Cir. 1983); *In re Lowry*, 32 F.3d 1579, 32 USPQ2d 1031 (Fed. Cir. 1994). Therefore, it would have been obvious to a person of ordinary skill in the art at the time the invention was made to choose any number of characters to represent the class, subclass, and specific drug because merely labeling the data differently from that in the prior art would have been obvious matter of design choice. *See In re Kuhle*, 526 F.2d 553, 555, 188 USPQ 7, 9 (CCPA 1975).

15. As per claim 56, Schrier in view of Bloom and Akers teach the method of claim 54 as described above. Schrier does not explicitly teach the multi-character cross reference code is associated with drug indications and contra-indications via ICD-9 codes. However, Akers further teaches the multi-character cross reference code is associated with drug indications and contra-indications via ICD-9 codes (see column 6, lines 32-36). It would have been obvious to one of ordinary skill in the art at the time of the invention to incorporate such coding features with the combined teachings of Schrier and Bloom for the reasons given above with respect to claim 49.

16. As per claim 59, Schrier in view of Bloom and Akers teach the method of claim 54 as described above. Schrier further teaches the drug therapy regimen data is automatically imported from a pharmacy dispensing system (see column 13, lines 38—53).

17. Claim 60 recites substantially similar limitations to those already addressed in claim 49 and, as such, is rejected for similar reasons as given above.

18. As per claim 61, Schrier in view of Bloom and Akers teach the method of claim 60 as described above. Schrier does not explicitly teach the identifying step highlights a particular drug in a patient's current drug regimen in addition to listing other drugs in the class or subclass with the same adverse reaction. Akers further teaches highlighting a particular drug in a patient's current drug regimen in addition to listing other drugs in the class or subclass with the

Art Unit: 3626

same adverse reaction (see column 4, line 49 – column 5, line 9). It would have been obvious to one of ordinary skill in the art at the time of the invention to incorporate such a feature with the combined teachings of Schrier and Bloom for the reasons given above with respect to claim 49.

19. Claims 58 is rejected under 35 U.S.C. 103(a) as being unpatentable over Schrier et al., U.S. Patent No. 6,317,719 in view of Bloom et al., U.S. Patent No. 6,070,761 and Akers et al., U.S. Patent No. 6,112,182 and further in view of Mayaud, U.S. Patent No. 5,845,255.

20. As per claim 58, Schrier in view of Bloom and Akers teaches the method of claim 54 as described above. Schrier does not explicitly teach generating a compliance percentage. Mayaud teaches a system for managing drug therapy regimen data and generating a compliance percentage (see column 28, lines 30-37, the Examiner notes that the recited formula equates to an amount of drug actually taken versus an amount prescribed which is what is reported on in Mayaud). It would have been obvious to one of ordinary skill in the art at the time of the invention to incorporate such a feature into the system of Schrier. One of ordinary skill in the art would have been motivated to incorporate such a feature for the purpose of enhancing the ready access to current, patient-specific drug information, as identified as an object of Schrier (see column 3, lines 36-59).

### ***Response to Arguments***

21. In the remarks filed 4/14/06, Applicants argue in substance that Schrier and Bloom fail to teach the feature of a multi-character therapeutic cross reference code as amended. The Examiner has fully considered these remarks but submits that they are now moot in view of the



Art Unit: 3626

new grounds of rejection detailed above. In particular, the Examiner has now relied upon the teachings of Akers for this newly added feature.

**Conclusion**

22. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Luke Gilligan whose telephone number is (571) 272-6770. The examiner can normally be reached on Monday-Friday 8am-5:30pm.

23. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Thomas can be reached on (571) 272-6776. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

24. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

6/23/06

  
C. LUKE GILLIGAN  
PATENT EXAMINER